Live Breaking News & Updates on Kymera Therapeutics Company Profile

Stay updated with breaking news from Kymera therapeutics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

HC Wainwright Reaffirms "Buy" Rating for Kymera Therapeutics (NASDAQ:KYMR)

HC Wainwright reiterated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $46.00 target price on the stock. Several other analysts have also recently weighed in on KYMR. JPMorgan Chase & Co. raised their target price on shares […] ....

Stifel Nicolaus , Comerica Bank , Principal Financial Group Inc , Jpmorgan Chase Co , Venture Fund Xlp Atlas , Mirae Asset Global Investments Co , Kymera Therapeutics Company Profile , Wolfe Research , Congress Asset Management Co , Kymera Therapeutics Inc , Ameritas Investment Partners Inc , Kymera Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Bruce Booth , Venture Fund , Investment Partners , Asset Global Investments , Asset Management , Principal Financial Group , Financial Group , Kymera Therapeutics Daily ,

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $41.10

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among […] ....

United States , Brucen Jacobs , Stifel Nicolaus , Wolfe Research , Jpmorgan Chase Co , Raymond James Associates , Venture Fund Xlp Atlas , Kymera Therapeutics Inc , Barclays Plc , Td Asset Management Inc , Allspring Global Investments Holdings , Kymera Therapeutics Company Profile , Securities Exchange Commission , Kymera Therapeutics , Get Free Report , Marketbeat Ratings , Venture Fund , Exchange Commission , Management Inc , Global Investments Holdings , State Retirement System , Get Free , Kymera Therapeutics Daily ,

Kymera Therapeutics (NASDAQ:KYMR) Issues Earnings Results, Beats Expectations By $0.04 EPS

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return […] ....

Piper Sandler , Securities Exchange Commission , Wolfe Research , Kymera Therapeutics Company Profile , Venture Fund Xlp Atlas , Jpmorgan Chase Co , Kymera Therapeutics Inc , Kymera Therapeutics , Get Free Report , Director Bruce Booth , Exchange Commission , Venture Fund , Truist Financial , Kymera Therapeutics Daily , Nasdaq Kymr ,

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target […] ....

United States , Piper Sandler , Stifel Nicolaus , Jared Gollob , Venture Fund Xlp Atlas , Td Asset Management Inc , Harbor Capital Advisors Inc , Raymond James Associates , Kymera Therapeutics Company Profile , Kymera Therapeutics Inc , Wolfe Research , Allspring Global Investments Holdings , Kymera Therapeutics , Get Free Report , Venture Fund , Capital Advisors , Management Inc , Global Investments Holdings , Arizona State Retirement System , Get Free , Kymera Therapeutics Daily , Nasdaq Kymr ,

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective […] ....

United States , Piper Sandler , Stifel Nicolaus , Quest Partners , Kymera Therapeutics Company Profile , China Universal Asset Management Co , Jpmorgan Chase Co , Venture Fund Xlp Atlas , Hsbc Holdings , Securities Exchange Commission , Allspring Global Investments Holdings , Kymera Therapeutics Inc , Kymera Therapeutics , Get Free Report , Venture Fund , Exchange Commission , Director Bruce Booth , Global Investments Holdings , State Retirement System , Universal Asset Management , Get Free , Kymera Therapeutics Daily , Nasdaq Kymr ,